Back

Humanization of the rpb9 locus in fission yeast reveals conserved and divergent roles of rpb9 and human POLR2I

Finkel, J. M.; Williams, M. G.; Nirmal, M. B.; Pandey, S.; Howe, E. D.; Liu, C. T.; Lohman, J. R.; Sharma, N.; Vo, T. V.

2026-04-04 synthetic biology
10.64898/2026.04.02.716003 bioRxiv
Show abstract

Background/ObjectivesRNA polymerase II is a multifunctional complex that is critical for gene regulation and environmental responses. Its POLR2I subunit in human is associated with various pathologies, including cancer chemoresistance. However, much of our understanding of how POLR2I could function indirectly derives from studies of its homologs in yeasts called Rpb9. Here, we endogenously humanized the rpb9 gene of the fission yeast Schizosaccharomyces pombe to examine the functional capabilities of POLR2I. MethodsWe edited the genomic rpb9 locus in S. pombe so that it encodes the human POLR2I protein, and investigated functional and structural conservation. ResultsWith our humanized yeast system, we find widespread functional complementation by human POLR2I of S. pombe rpb9 roles in yeast growth, chronological aging, and stress responses. We also find that POLR2I complements novel roles for yeast rpb9 in facultative heterochromatin assembly, resistance against the chemotherapy 5-fluorouracil, and resistance against the fungicide thiabendazole. In contrast, we find that POLR2I cannot complement the role of rpb9 in resistance against the transcription elongation inhibitor 6-azauracil (6-AU) in our system. Interestingly, POLR2I could complement 6-AU resistance if ectopically expressed. Lastly, we observe extensive structural homology between Rpb9 and POLR2I proteins. ConclusionsOur study establishes an endogenous cross-species gene complementation strategy that uncovers both conserved and rewired functions of fission yeast rpb9 and its human homolog, POLR2I. In addition to validating conserved roles, we also identified conservation of previously unrecognized roles of rpb9 in heterochromatin formation and chemoresistance.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nucleic Acids Research
1128 papers in training set
Top 0.4%
19.8%
2
PLOS Genetics
756 papers in training set
Top 1%
10.3%
3
Scientific Reports
3102 papers in training set
Top 8%
9.3%
4
Chromosome Research
18 papers in training set
Top 0.1%
3.7%
5
Nature Communications
4913 papers in training set
Top 39%
3.6%
6
Open Biology
95 papers in training set
Top 0.1%
3.6%
50% of probability mass above
7
PLOS ONE
4510 papers in training set
Top 41%
3.3%
8
Cell Reports
1338 papers in training set
Top 18%
2.9%
9
eLife
5422 papers in training set
Top 32%
2.6%
10
Philosophical Transactions of the Royal Society B
51 papers in training set
Top 2%
2.1%
11
Journal of Molecular Biology
217 papers in training set
Top 1%
2.1%
12
ACS Synthetic Biology
256 papers in training set
Top 1%
2.1%
13
G3: Genes, Genomes, Genetics
222 papers in training set
Top 0.3%
1.9%
14
EMBO Reports
88 papers in training set
Top 0.1%
1.9%
15
BMC Bioinformatics
383 papers in training set
Top 4%
1.8%
16
Communications Biology
886 papers in training set
Top 8%
1.7%
17
iScience
1063 papers in training set
Top 15%
1.7%
18
Biochemistry
130 papers in training set
Top 0.8%
1.7%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 34%
1.5%
20
Computational and Structural Biotechnology Journal
216 papers in training set
Top 5%
1.4%
21
Genome Research
409 papers in training set
Top 3%
1.0%
22
BMC Biology
248 papers in training set
Top 3%
1.0%
23
G3 Genes|Genomes|Genetics
351 papers in training set
Top 2%
1.0%
24
International Journal of Molecular Sciences
453 papers in training set
Top 12%
1.0%
25
Journal of Biological Chemistry
641 papers in training set
Top 4%
0.8%
26
The Plant Journal
197 papers in training set
Top 3%
0.8%
27
ACS Omega
90 papers in training set
Top 4%
0.7%
28
Genetics
225 papers in training set
Top 4%
0.7%
29
Bioinformatics
1061 papers in training set
Top 10%
0.7%
30
mBio
750 papers in training set
Top 12%
0.7%